Orphan Drug Prices Threatened in Austerity-Minded Europe

Antoine Antoniol/Bloomberg

As more medicines win approval to treat diseases that affect no more than 5 in 10,000 people, austerity-conscious governments in Europe are applying the same pressure to so-called orphan drugs that they do to widely prescribed medicines for heart disease and diabetes.